Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP352 (bexicaserin) in developmental and epileptic encephalopathy
NCT05626634Phase 2Completed
- Sponsor
- Longboard Pharmaceuticals
- Start
- Nov 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of bexicaserin in developmental and epileptic encephalopathy (DEE), Dravet syndrome and Lennox-Gastaut syndrome (LGS), sponsored by Longboard Pharmaceuticals. Primary endpoints: Treatment-emergent Adverse Events at 52 weeks, Columbia-Suicide Severity Rating Scale Response at 52 weeks and 1 more. Started Nov 2022; status: completed.
02
Drugs
bexicaserin
03
Conditions
developmental and epileptic encephalopathy (DEE)Dravet syndromeLennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on NCT05626634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05626634.